DOCSLIB.ORG

Guidelines for Reproductive Toxicity Risk Assessment

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Guidelines for Reproductive Toxicity Risk Assessment EPA/630/R-96/009 October 1996 Guidelines for Reproductive Toxicity Risk Assessment Published on October 31, 1996, Federal Register 61(212):56274-56322 These guidelines replace two proposed guidelines: Proposed Guidelines for Female Reproductive Risk and Proposed Guidelines for Male Reproductive Risk, both dated June 30, 1988. Risk Assessment Forum U.S. Environmental Protection Agency Washington, DC DISCLAIMER This document has been reviewed in accordance with U.S. Environmental Protection Agency policy and approved for publication. Mention of trade names or commercial products does not constitute endorsement or recommendation for use. Note: This document represents the final guidelines. A number of editorial corrections have been made during conversion and subsequent proofreading to ensure the accuracy of this publication. iii CONTENTS List of Tables ................................................................. vi Federal Register Preamble ....................................................... vii Part A: Guidelines for Reproductive Toxicity Risk Assessment 1. Overview ..................................................................1 2. Definitions and Terminology ....................................................5 3. Hazard Characterization for Reproductive Toxicants ..................................6 3.1. Laboratory Testing Protocols ..............................................7 3.1.1. Introduction .....................................................7 3.1.2. Duration of Dosing ................................................7 3.1.3. Length of Mating Period ...........................................8 3.1.4. Number of Females Mated to Each Male ...............................8 3.1.5. Single- and Multigeneration Reproduction Tests ..........................8 3.1.6. Alternative Reproductive Tests ......................................11 3.1.7. Additional Test Protocols That May Provide Reproductive Data .............12 3.2. Endpoints for Evaluating Male and Female Reproductive Toxicity in Test Species ..........................................................14 3.2.1. Introduction ....................................................14 3.2.2. Couple-Mediated Endpoints .......................................15 3.2.2.1. Fertility and Pregnancy Outcomes ............................15 3.2.2.2. Sexual Behavior .........................................22 3.2.3. Male-Specific Endpoints ..........................................24 3.2.3.1. Introduction ............................................24 3.2.3.2. Body Weight and Organ Weights ............................24 3.2.3.3. Histopathologic Evaluations .................................27 3.2.3.4. Sperm Evaluations .......................................29 3.2.3.5. Paternally Mediated Effects on Offspring .......................33 3.2.4. Female-Specific Endpoints .........................................34 3.2.4.1. Introduction ............................................34 3.2.4.2. Body Weight, Organ Weight, Organ Morphology, and Histology .....35 3.2.4.3. Oocyte Production .......................................41 3.2.4.4. Alterations in the Female Reproductive Cycle ...................42 3.2.4.5. Mammary Gland and Lactation ..............................44 3.2.4.6. Reproductive Senescence ..................................45 3.2.5. Developmental and Pubertal Alterations ...............................45 3.2.5.1. Developmental Effects .....................................45 iv CONTENTS (continued) 3.2.5.2. Effects on Puberty ........................................46 3.2.5.3. Adverse Effects ..........................................47 3.2.6. Endocrine Evaluations ............................................47 3.2.6.1. Adverse Effects ..........................................50 3.2.7. In Vitro Tests of Reproductive Function ...............................50 3.3. Human Studies ........................................................51 3.3.1. Epidemiologic Studies ............................................51 3.3.1.1. Selection of Outcomes for Study .............................52 3.3.1.2. Reproductive History Studies ...............................55 3.3.1.3. Community Studies and Surveillance Programs ..................56 3.3.1.4. Identification of Important Exposures for Reproductive Effects ................................................57 3.3.1.5. General Design Considerations ..............................58 3.3.2. Examination of Clusters, Case Reports, or Series ........................61 3.4. Pharmacokinetic Considerations ...........................................62 3.5. Comparisons of Molecular Structure ........................................64 3.6. Evaluation of Dose-Response Relationships ...................................64 3.7. Characterization of the Health-Related Database ...............................66 4. Quantitative Dose-Response Analysis ............................................71 4.1. Utilization of Information in Risk Characterization ...............................74 5. Exposure Assessment ........................................................75 6. Risk Characterization ........................................................80 6.1. Overview ............................................................80 6.2. Integration of Hazard Characterization, Quantitative Dose-Response, and Exposure Assessments ...............................................81 6.3. Descriptors of Reproductive Risk ..........................................83 6.3.1. Distribution of Individual Exposures ..................................88 6.3.2. Population Exposure .............................................88 6.3.3. Margin of Exposure ..............................................89 6.3.4. Distribution of Exposure and Risk for Different Subgroups .................89 6.3.4.1. Highly Exposed ..........................................89 6.3.4.2. Highly Susceptible ........................................90 6.3.5. Situation-Specific Information ......................................91 6.3.6. Evaluation of the Uncertainty in the Risk Descriptors ......................92 6.4. Summary and Research Needs ............................................92 7. References ................................................................93 v CONTENTS (continued) Part B: Response to Science Advisory Board and Public Comments 1. Introduction ..............................................................115 2. Response to Science Advisory Board Comments ..................................115 3. Response to Public Comments ................................................117 vi LIST OF TABLES Table 1. Default assumptions in reproductive toxicity risk assessment ........................3 Table 2. Couple-mediated endpoints of reproductive toxicity .............................16 Table 3. Selected indices that may be calculated from endpoints of reproductive toxicity in test species ...................................................17 Table 4. Male-specific endpoints of reproductive toxicity ................................25 Table 5. Female-specific endpoints of reproductive toxicity ..............................36 Table 6. Categorization of the health-related database ..................................68 Table 7. Guide for developing chemical-specific risk characterizations for reproductive effects .....................................................84 vii GUIDELINES FOR REPRODUCTIVE TOXICITY RISK ASSESSMENT [FRL-5630-6] AGENCY: U.S. Environmental Protection Agency ACTION: Notice of availability of final Guidelines for Reproductive Toxicity Risk Assessment SUMMARY: The U.S. Environmental Protection Agency (EPA) is today publishing in final form a document entitled Guidelines for Reproductive Toxicity Risk Assessment (hereafter “Guidelines”). These Guidelines were developed as part of an interoffice guidelines development program by a Technical Panel of the Risk Assessment Forum. They were proposed initially in 1988 as separate guidelines for the female and male reproductive systems. Subsequently, based upon the public comments and Science Advisory Board (SAB) recommendations, changes made included combining those two guidelines, integrating the hazard identification and dose-response sections, assuming as a default that an agent for which sufficient data were available on only one sex may also affect reproductive function in the other sex, expansion of the section on interpretation of female endpoints, and consideration of the benchmark dose approach for quantitative risk assessment. These Guidelines were made available again for public comment and SAB review in 1994. This notice describes the scientific basis for concern about exposure to agents that cause reproductive toxicity, outlines the general process for assessing potential risk to humans from exposure to environmental agents, and addresses Science Advisory Board and public comments on the 1994 Proposed Guidelines for Reproductive Toxicity Risk Assessment. Subsequent reviews have included the Agency’s Risk Assessment Forum and interagency comment by members of subcommittees of the Committee on the Environment and Natural Resources of the Office of Science and Technology Policy. The EPA appreciates the efforts of all participants in the process and has tried to address their recommendations in these Guidelines. EFFECTIVE DATE: The Guidelines will be effective October 31, 1996. viii ADDRESSES: The Guidelines will be made available in the following ways: (1) The electronic version will be accessible on EPA’s Office of Research
Load more

Recommended publications
  • FDA Guidance on Establishing Pregnancy Exposure Registries
    Guidance for Industry Establishing Pregnancy Exposure Registries U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) August 2002 Clinical/Medical Guidance for Industry Establishing Pregnancy Exposure Registries Additional copies are available from: Office of Training and Communications Division of Communications Management Drug Information Branch, HFD-210 5600 Fishers Lane Rockville, MD 20857 (Tel) 301-827-4573 http://www.fda.gov/cder/guidance/index.htm or Office of Communication, Training, and Manufacturers Assistance (HFM-40) Center for Biologics Evaluation and Research (CBER) 1401 Rockville Pike, Rockville, MD 20852-1448 http://www.fda.gov/cber/guidelines.htm (Fax) 888-CBERFAX or 301-827-3844 (Voice Information) 800-835-4709 or 301-827-1800 U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) August 2002 Clinical/Medical TABLE OF CONTENTS I. INTRODUCTION................................................................................................................. 1 II. BACKGROUND ...................................................................................................................1 III. WHAT IS A PREGNANCY EXPOSURE REGISTRY? .................................................. 2 IV. WHAT MEDICAL PRODUCTS MAKE GOOD REGISTRY CANDIDATES?........... 3 V. WHEN SHOULD SUCH A REGISTRY BE ESTABLISHED?......................................
    [Show full text]
  • Safety of Immunization During Pregnancy a Review of the Evidence
    Safety of Immunization during Pregnancy A review of the evidence Global Advisory Committee on Vaccine Safety © World Health Organization 2014 All rights reserved. Publications of the World Health Organization are available on the WHO website (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications –whether for sale or for non-commercial distribution– should be addressed to WHO Press through the WHO website (www.who.int/about/licensing/copyright_form/en/index.html). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied.
    [Show full text]
  • Conventional Gasoline
    Conventional Gasoline M a t e r i a l S a f e t y D a t a S h e e t 1. PRODUCT AND COMPANY IDENTIFICATION Product Name: Conventional Gasoline MSDS Code: 251720 Synonyms: Gasoline, Unleaded, Conventional (All Grades); Gasoline, Low Sulfur Unleaded (All Grades) Intended Use: Fuel Responsible Party: ConocoPhillips 600 N. Dairy Ashford Houston, Texas 77079-1175 Customer Service: 800-640-1956 Technical Information: 800-255-9556 MSDS Information: Phone: 800-762-0942 Email: [email protected] Internet: http://w3.conocophillips.com/NetMSDS/ Emergency Telephone Numbers: Chemtrec: 800-424-9300 (24 Hours) California Poison Control System: 800-356-3219 2. HAZARDS IDENTIFICATION Emergency Overview NFPA DANGER! Extremely Flammable Liquid and Vapor Skin Irritant Aspiration Hazard Appearance: Clear to amber Physical Form: Liquid Odor: Gasoline Potential Health Effects Eye: Contact may cause mild eye irritation including stinging, watering, and redness. Skin: Skin irritant. Contact may cause redness, itching, a burning sensation, and skin damage. Prolonged or repeated contact can defat the skin, causing drying and cracking of the skin, and possibly dermatitis (inflammation). Not acutely toxic by skin absorption, but prolonged or repeated skin contact may be harmful (see Section 11). Inhalation (Breathing): Low to moderate degree of toxicity by inhalation. Ingestion (Swallowing): Low degree of toxicity by ingestion. ASPIRATION HAZARD - This material can enter lungs during swallowing or vomiting and cause lung inflammation and damage. Signs and Symptoms: Effects of overexposure may include nausea, vomiting, flushing, blurred vision, tremors, respiratory failure, signs of nervous system depression (e.g., headache, drowsiness, dizziness, loss of coordination, disorientation and fatigue), unconsciousness, convulsions, death.
    [Show full text]
  • OECD Conceptual Framework for Testing and Assessment of Endocrine Disrupters As a Basis for Regulation of Substances with Endocrine Disrupting Properties
    OECDOECD ConceptualConceptual FrameworkFramework for forTesting Testing and and Assessment Assessment of Endocrineof EndocrineDisrupters Disruptersas a basis asfor aregulation basis of forsubstances regulation with of substances endocrine disrupting with endocrineproperties disrupting properties Ulla Hass, Majken Dalgaard, Kirsten Jarfelt and Thuri S.A. Kledal Department of Toxicology and Risk Assessment, Danish Institute for Food and Veterinary Research, Denmark TemaNord 2004:555 OECD Conceptual Framework for Testing and Assessment of Endocrine Disrupters as a basis for regulation of substances with endocrine disrupting properties TemaNord 2004:555 © Nordic Council of Ministers, Copenhagen 2004 ISBN 92-893-1073-1 ISSN 0908-6692 Nordic Council of Ministers Nordic Council Store Strandstræde 18 Store Strandstræde 18 DK-1255 Copenhagen K DK-1255 Copenhagen K Phone (+45) 3396 0200 Phone (+45) 3396 0400 Fax (+45) 3396 0202 Fax (+45) 3311 1870 www.norden.org Nordic Environmental Co-operation Environmental co-operation is aimed at contributing to the improvement of the environment and forestall problems in the Nordic countries as well as on the international scene. The co- operation is conducted by the Nordic Committee of Senior Officials for Environmental Affairs. The co-operation endeavours to advance joint aims for Action Plans and joint projects, exchange of information and assistance, e.g. to Eastern Europe, through the Nordic Environmental Finance Corporation (NEFCO). The Nordic Council of Ministers was established in 1971. It submits proposals on co-operation between the governments of the five Nordic countries to the Nordic Council, implements the Council's recommendations and reports on results, while directing the work carried out in the targeted areas. The Prime Ministers of the five Nordic countries assume overall responsibility for the co-operation measures, which are co-ordinated by the ministers for co-operation and the Nordic Co-operation committee.
    [Show full text]
  • Fighting Bisphenol A-Induced Male Infertility: the Power of Antioxidants
    antioxidants Review Fighting Bisphenol A-Induced Male Infertility: The Power of Antioxidants Joana Santiago 1 , Joana V. Silva 1,2,3 , Manuel A. S. Santos 1 and Margarida Fardilha 1,* 1 Department of Medical Sciences, Institute of Biomedicine-iBiMED, University of Aveiro, 3810-193 Aveiro, Portugal; [email protected] (J.S.); [email protected] (J.V.S.); [email protected] (M.A.S.S.) 2 Institute for Innovation and Health Research (I3S), University of Porto, 4200-135 Porto, Portugal 3 Unit for Multidisciplinary Research in Biomedicine, Institute of Biomedical Sciences Abel Salazar, University of Porto, 4050-313 Porto, Portugal * Correspondence: [email protected]; Tel.: +351-234-247-240 Abstract: Bisphenol A (BPA), a well-known endocrine disruptor present in epoxy resins and poly- carbonate plastics, negatively disturbs the male reproductive system affecting male fertility. In vivo studies showed that BPA exposure has deleterious effects on spermatogenesis by disturbing the hypothalamic–pituitary–gonadal axis and inducing oxidative stress in testis. This compound seems to disrupt hormone signalling even at low concentrations, modifying the levels of inhibin B, oestra- diol, and testosterone. The adverse effects on seminal parameters are mainly supported by studies based on urinary BPA concentration, showing a negative association between BPA levels and sperm concentration, motility, and sperm DNA damage. Recent studies explored potential approaches to treat or prevent BPA-induced testicular toxicity and male infertility. Since the effect of BPA on testicular cells and spermatozoa is associated with an increased production of reactive oxygen species, most of the pharmacological approaches are based on the use of natural or synthetic antioxidants.
    [Show full text]
  • Toxicological Profile for Bisphenol A
    TT TOXICOLOGICAL PROFILE FOR BISPHENOL A September 2009 Integrated Risk Assessment Branch Office of Environmental Health Hazard Assessment California Environmental Protection Agency Toxicological Profile for Bisphenol A September 2009 Prepared by Office of Environmental Health Hazard Assessment Prepared for Ocean Protection Council Under an Interagency Agreement, Number 07-055, with the State Coastal Conservancy LIST OF CONTRIBUTORS Authors Jim Carlisle, D.V.M., Ph.D., Senior Toxicologist, Integrated Risk Assessment Branch Dave Chan, D. Env., Staff Toxicologist, Integrated Risk Assessment Branch Mari Golub, Ph.D., Staff Toxicologist, Reproductive and Cancer Hazard Assessment Branch Sarah Henkel, Ph.D., California Sea Grant Fellow, California Ocean Science Trust Page Painter, M.D., Ph.D., Senior Toxicologist, Integrated Risk Assessment Branch K. Lily Wu, Ph.D., Associate Toxicologist, Reproductive and Cancer Hazard Assessment Branch Reviewers David Siegel, Ph.D., Chief, Integrated Risk Assessment Branch i Table of Contents Executive Summary ................................................................................................................................ iv Use and Exposure ............................................................................................................................... iv Environmental Occurrence ................................................................................................................. iv Effects on Aquatic Life ......................................................................................................................
    [Show full text]
  • ECETOC Guidance on Dose Selection
    ECETOC Guidance on Dose Selection Technical Report No. 138 EUROPEAN CENTRE OFOR EC TOXICOLOGY AND TOXICOLOGY OF CHEMICALS ECETOC Guidance on Dose Selection ECETOC Guidance on Dose Selection Technical Report No. 138 Brussels, March 2021 ISSN-2079-1526-138 (online) ECETOC TR No. 138 1 ECETOC Guidance on Dose Selection 224504 ECETOC Technical Report No. 138 © Copyright – ECETOC AISBL European Centre for Ecotoxicology and Toxicology of Chemicals Rue Belliard 40, B-1040 Brussels, Belgium. All rights reserved. No part of this publication may be reproduced, copied, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise without the prior written permission of the copyright holder. Applications to reproduce, store, copy or translate should be made to the Secretary General. ECETOC welcomes such applications. Reference to the document, its title and summary may be copied or abstracted in data retrieval systems without subsequent reference. The content of this document has been prepared and reviewed by experts on behalf of ECETOC with all possible care and from the available scientific information. It is provided for information only. ECETOC cannot accept any responsibility or liability and does not provide a warranty for any use or interpretation of the material contained in the publication. ECETOC TR No. 138 2 ECETOC Guidance on Dose Selection ECETOC Guidance on Dose Selection Table of Contents 1. SUMMARY 6 2. INTRODUCTION, BACKGROUND AND PRINCIPLES 9 2.1. Background and Principles 9 2.2. Current Regulatory Framework and Guidance 10 2.2.1. Historical perspectives and the evolution of test guidelines 10 2.2.2.
    [Show full text]
  • Acaricide Mode of Action Classification: a Key to Effective Acaricide Resistance Management Insecticide Resistance Action Committee
    Acaricide Mode of Action Classification: A key to effective acaricide resistance management Insecticide Resistance Action Committee www.irac-online.org Introduction Effective IRM strategies: Sequences or alternations of MoA IRAC promotes the use of a Mode of Action (MoA) classification of All effective pesticide resistance management strategies seek to minimise the selection of resistance to any one type of MoA w MoA x MoA y MoA z MoA w MoA x insecticides and acaricides as the basis for effective and sustainable pesticide. In practice, alternations, sequences or rotations of compounds from different MoA groups provide sustainable and resistance management. Acaricides are allocated to specific groups based effective resistance management for acarine pests. This ensures that selection from compounds in the same MoA group is on their target site. Reviewed and re-issued periodically, the IRAC MoA minimised, and resistance is less likely to evolve. Sequence of acaricides through season classification list provides farmers, growers, advisors, extension staff, consultants and crop protection professionals witH a guide to the selection of Applications are often arranged into MoA spray windows or blocks that are defined by the stage of crop development and the biology of the pest species of concern. Local expert advice should acaricides and insecticides in resistance management programs. Effective always be followed witH regard to spray windows and timings. Several sprays may be possible witHin each spray window but it is generally essential to ensure that successive generations of the Resistance management of this type preserves the utility and diversity of pest are not treated witH compounds from the same MoA group.
    [Show full text]
  • Development of an Equine Behavior Chamber and Effects of Amitraz, Detomidine, and Acepromazine on Spontaneous Locomotor Activity
    Reprinted in the IVIS website with the permission of the AAEP Close window to return to IVIS RACING REGULATORY Development of an Equine Behavior Chamber and Effects of Amitraz, Detomidine, and Acepromazine on Spontaneous Locomotor Activity J. Daniel Harkins, DVM, PhD; Thomas Tobin, DVM, PhD; and Antonio Queiroz-Neto, DVM, PhD The locomotor chamber is a sensitive and highly reproducible tool for measuring spontaneous locomotor activity in the horse. It allows investigators to determine an agent’s average time of onset, duration, and intensity of effect on movement. Authors’ addresses: Maxwell H. Gluck Equine Research Center and the Department of Veterinary Science, University of Kentucky, Lexington, KY 40506 (Harkins and Tobin) and Universidade Estadual Paulista, Campus de Jaboticabal, Brazil (Queiroz-Neto). ௠ 1997 AAEP. 1. Introduction dine HCl (0.02, 0.04, and 0.08 mg/kg), amitraz (0.05, Horses in a confined space instinctively move around 0.1, and 0.15 mg/kg), and acepromazine (0.002, 0.006, their environment. This movement is defined as 0.018, and 0.054 mg/kg) were injected to assess the spontaneous locomotor activity.1 Baseline locomo- effect of those agents on locomotor activity. In a tor activity in a large number of horses was mea- separate experiment, yohimbine HCl (0.12 mg/kg) sured in a behavior chamber, which was validated by was administered following an injection of amitraz quantifying behavioral responses to fentanyl and (0.15 mg/kg) to assess the reversal effect of that xylazine. The goal of this project was to develop agent. An analysis of variance with repeated mea- protocols for the measurement of locomotor activity sures was used to compare control and treatment in the freely moving horse.
    [Show full text]
  • Interaction Profile
    INTERACTION PROFILE FOR: PERSISTENT CHEMICALS FOUND IN FISH (CHLORINATED DIBENZO-p-DIOXINS, HEXACHLOROBENZENE, p,p’-DDE, METHYLMERCURY, and POLYCHLORINATED BIPHENYLS) U.S. Department of Health and Human Services Public Health Service Agency for Toxic Substances and Disease Registry May 2004 iii ACKNOWLEDGMENT The Agency for Toxic Substances and Disease Registry (ATSDR) wishes to thank the U.S. Environmental Protection Agency (EPA) for its support in the production of this Interaction Profile. v PREFACE The Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA) mandates that the Agency for Toxic Substances and Disease Registry (ATSDR) shall assess whether adequate information on health effects is available for the priority hazardous substances. Where such information is not available or under development, ATSDR shall, in cooperation with the National Toxicology Program, initiate a program of research to determine these health effects. The Act further directs that where feasible, ATSDR shall develop methods to determine the health effects of substances in combination with other substances with which they are commonly found. To carry out the legislative mandate, ATSDR’s Division of Toxicology (DT) has developed and coordinated a mixtures program that includes trend analysis to identify the mixtures most often found in environmental media, in vivo and in vitro toxicological testing of mixtures, quantitative modeling of joint action, and methodological development for assessment of joint toxicity. These efforts are interrelated. For example, the trend analysis suggests mixtures of concern for which assessments need to be conducted. If data are not available, further research is recommended. The data thus generated often contribute to the design, calibration or validation of the methodology.
    [Show full text]
  • Why Should I Get My Bulls Fertility Tested? by Travis A
    Ask the Vet: Why should I get my bulls fertility tested? By Travis A. Hawkins, DVM Akron Veterinary Clinic Cattle producers obtain their income from selling calves. If you remember back to your high school health class, it takes a male and a female to make a baby, so a fertile bull is half the equation. However, the bull becomes even more important because in livestock production we typically have a small number of males running with a considerably larger number of females. Therefore, a ‘dud’ bull can result in few or no pregnancies despite perfectly healthy cows. A mature bull should be able to easily service up to 40 cows, though many producers use many more bulls as ‘insurance’ in case of fertility problems. The cost of purchasing and maintaining these extra bulls can be quite significant. Fertility testing of bulls is a fairly simple procedure. We use an electrical stimulus to induce a semen sample from the bull. Then we examine the sperm under a microscope. Ideally, there is a large concentration of ‘motile’ sperm, which means there are a lot of little guys alive and swimming around. We then turn the microscope up to a higher power and examine a few of the sperm individually to see that they have developed correctly and do not have any abnormalities that would impair their ability to fertilize an egg. One thing that I try to emphasize when fertility testing is that it is simply a snapshot of the bull’s performance at this point in time. If your bull is good today, an injury or abnormally hot weather could cause him to become infertile at any time.
    [Show full text]
  • Fertility Case Reviews & Recommendations
    FERTILITY UPDATE SHADY GROVE FERTILITY Four Fertility Case Reviews & Recommendations When Physicians Collaborate, Patients Benefit Over the past 25 years, the physicians of Shady Grove Fertility have collaborated extensively with OB/GYN providers to assist with their challenging infertility cases. These colleague-to-colleague collaborations offer a mutually beneficial exchange of information and expertise, with the ultimate goal of providing a seamless continuum of care for patients. Below are just a few recent case review collaborations that demonstrate this productive exchange of information. CASE REVIEW #1 CASE REVIEW #2 Symptoms Symptoms Age TTC • Cycles vary between 60 to 90 days Age TTC • Painful periods 29 14 months • BMI 29 27 7 months • History of endometriosis diagnosed at • History of excess body hair, acne operative laparoscopy 3 years ago Test Results Test Results Painful • Day 3 bloods: AMH 4.7, FSH 5.6, LH 10, Irregular • Pelvic ultrasound: normal uterus; complex Periods Estradiol 50 Cycles right ovarian cyst measuring 3x3cm • Pelvic ultrasound: normal uterus; multiple suggestive of an endometrioma; left ovarian follicles on both ovaries cyst measuring 3x2cm suggestive of an • TSH, prolactin, 17OHP, lipid profile, HgbA1C normal endometrioma Diagnosis to Consider • Day 3 bloods: Not completed Polycystic ovary syndrome (PCOS) Diagnosis to Consider Recommendation Endometriosis, stage 4 After ruling out pregnancy and verifying no other fertility problems via Recommendation HSG and semen analysis, consider treatment with Clomid 50mg daily Patients with known advanced stage endometriosis who wish to have from days 5-9 to induce ovulation. A luteal progesterone > 3pg/ml and a children should consult with a fertility specialist before having additional menstrual calendar are helpful to determine if ovulation has occurred.
    [Show full text]